{
  "version": "2025.1",
  "last_updated": "2025-01-26",
  "source": "NCCN Clinical Practice Guidelines in Oncology",
  "disclaimer": "Research Use Only - Not for Clinical Diagnosis. Simplified version of NCCN guidelines.",
  
  "guidelines": {
    "breast": {
      "HER2_positive": {
        "first_line": [
          {
            "therapy": "trastuzumab + pertuzumab + taxane",
            "category": "1",
            "indication": "First-line HER2+ metastatic breast cancer",
            "evidence": "High",
            "rationale": "CLEOPATRA trial showed improved OS"
          },
          {
            "therapy": "trastuzumab deruxtecan (T-DXd)",
            "category": "1",
            "indication": "HER2+ metastatic breast cancer",
            "evidence": "High",
            "rationale": "DESTINY-Breast03 showed superiority over T-DM1"
          }
        ],
        "second_line": [
          {
            "therapy": "trastuzumab deruxtecan (T-DXd)",
            "category": "1",
            "indication": "Post-trastuzumab progression",
            "evidence": "High",
            "rationale": "DESTINY-Breast01 and 03 trials"
          },
          {
            "therapy": "tucatinib + trastuzumab + capecitabine",
            "category": "1",
            "indication": "Post-trastuzumab progression",
            "evidence": "High",
            "rationale": "HER2CLIMB trial"
          }
        ]
      },
      "BRCA_mutant": {
        "all_lines": [
          {
            "therapy": "PARP inhibitor (olaparib, talazoparib)",
            "category": "1",
            "indication": "Germline BRCA1/2 mutation, HER2-negative",
            "evidence": "High",
            "rationale": "OlympiAD and EMBRACA trials"
          },
          {
            "therapy": "platinum chemotherapy",
            "category": "2A",
            "indication": "BRCA1/2 mutation, HR deficiency",
            "evidence": "Moderate",
            "rationale": "TNT trial, increased sensitivity to platinum"
          }
        ]
      }
    },
    "lung": {
      "EGFR_mutant": {
        "first_line": [
          {
            "therapy": "osimertinib",
            "category": "1",
            "indication": "EGFR exon 19 del or L858R mutation",
            "evidence": "High",
            "rationale": "FLAURA trial"
          }
        ]
      },
      "ALK_rearranged": {
        "first_line": [
          {
            "therapy": "alectinib",
            "category": "1",
            "indication": "ALK+ NSCLC",
            "evidence": "High",
            "rationale": "ALEX trial"
          }
        ]
      }
    },
    "myeloma": {
      "newly_diagnosed": {
        "transplant_eligible": [
          {
            "therapy": "bortezomib + lenalidomide + dexamethasone (VRd)",
            "category": "1",
            "indication": "Transplant-eligible NDMM",
            "evidence": "High",
            "rationale": "SWOG S0777 trial"
          }
        ],
        "transplant_ineligible": [
          {
            "therapy": "daratumumab + lenalidomide + dexamethasone (DRd)",
            "category": "1",
            "indication": "Transplant-ineligible NDMM",
            "evidence": "High",
            "rationale": "MAIA trial"
          }
        ]
      },
      "relapsed_refractory": {
        "first_relapse": [
          {
            "therapy": "daratumumab + pomalidomide + dexamethasone",
            "category": "1",
            "indication": "Relapsed/refractory MM",
            "evidence": "High",
            "rationale": "APOLLO and OPTIMISMM trials"
          }
        ]
      }
    }
  },
  
  "category_definitions": {
    "1": "Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.",
    "2A": "Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.",
    "2B": "Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.",
    "3": "Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate."
  },
  
  "evidence_level_definitions": {
    "High": "Randomized controlled trials with statistically significant improvements in OS or PFS",
    "Moderate": "Non-randomized trials, cohort studies, or RCTs with surrogate endpoints",
    "Low": "Case series, expert opinion, or extrapolated data"
  }
}


